Indeed, the possibility of a new therapeutic target for prophylactic migraine treatment is exciting; however, it is important to consider that PACAP and PAC1 receptor participate in numerous physiological processes (see Fig. 2). Here, ADCYAP1 is linked to migraine disorder.